• Study: Chemotherapy agent did not improve survival in patients with triple-negative breast cancer

    3 days ago - By News Medical

    Treating patients who had early-stage triple-negative breast cancer with the chemotherapy agent capecitabine after they completed surgery and standard chemotherapy did not significantly improve disease-free or overall survival compared with observation, according to data from the randomized, phase III GEICAM/CIBOMA clinical trial presented at the 2018 San Antonio Breast Cancer Symposium, held Dec. 4-8.
    Read more ...

     

  • Carvedilol Lowers Heart Damage in Breast Cancer

    Carvedilol Lowers Heart Damage in Breast Cancer

    3 days ago - By Medindia Health

    Impaired left ventricle, the main heart damage caused by trastuzumab among breast cancer patients could be lowered by taking carvedilol
    Read more ...

     

  • Patients with breast cancer who respond to neoadjuvant treatment may not need adjuvant chemotherapy

    3 days ago - By Healio

    SAN ANTONIO - Patients with breast cancer who achieved pathologic complete response to neoadjuvant chemotherapy attained similar survival outcomes regardless of whether they underwent adjuvant chemotherapy, according to results of a comprehensive patient-level meta-analysis presented at San Antonio Breast Cancer Symposium.
    The consistency of outcomes with regard to recurrence and survival likely reflects tumor biology and indicates adjuvant chemotherapy could potentially be omitted in certain circumstances, Laura M. Spring, MD, medical oncologist at Massachusetts General Hospital Cancer
    Read more ...

     

  • Researchers identify gene alterations linked to certain metastatic breast cancers

    3 days ago - By Healio

    SAN ANTONIO - Ten driver gene alterations appeared more common among a cohort of patients with metastatic hormone receptor-positive, HER2-negative breast cancer than those with early-stage disease, according to study results presented at San Antonio Breast Cancer Symposium.
    “Metastatic breast cancers acquire new genomic alterations, suggesting a genome evolution or clonal selection,” Fabrice André, MD, PhD, associate professor in the department of medical oncology at Institute Gustave Roussy in France, said during a presentation.
    Little is known about the genomic
    Read more ...

     

  • Delayed initiation of adjuvant chemotherapy linked to poorer outcomes in triple-negative breast cancer

    3 days ago - By Healio

    SAN ANTONIO - Longer delays to initiation of adjuvant chemotherapy appeared associated with poorer outcomes among patients with triple-negative breast cancer, according to retrospective study results presented at San Antonio Breast Cancer Symposium.
    Patients who started adjuvant chemotherapy more than 30 days after surgery achieved shorter DFS, distant-relapse free survival and OS.
    “These results represent a feasible opportunity for improving the outcomes of [patients with triple-negative breast cancer],” Zaida Morante, MD, medical oncologist at Instituto Nacional de
    Read more ...

     

  • Some elderly patients with breast cancer less likely to receive adjuvant chemotherapy despite OS benefit

    3 days ago - By Healio

    SAN ANTONIO - Several factors influenced receipt of adjuvant chemotherapy among a cohort of elderly women with breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.
    However, adjuvant chemotherapy appeared associated with an OS benefit regardless of many of those key factors, including age, hormone receptor status and disease stage.
    “In 2018, there was an estimated 266,000 cases of breast cancer. Of these, around 90% of cases were diagnosed at local or regional stages and the majority in older-aged adults,” Shreya Sinha, MD, fellow
    Read more ...